The U.S. and Europe Still Dominate Global mAb Approvals, but China Is Accelerating
Cumulative global mAb approvals by region of origin, 2017–25
Line chart of cumulative global monoclonal antibody approvals by region of origin from 2017 to 2025, where the U.S. or Europe leads with approximately 23 approvals and China shows accelerating growth reaching 5 by 2025, while Japan and Canada remain flat.
